Beckman Coulter
This article was originally published in The Gray Sheet
Executive Summary
Beckman Coulter: Proceeds of a planned $400 mil. private placement of senior notes will be used to prepay a portion of its existing bank borrowings - incurred to fund the combination of Beckman Instruments and Coulter Corporation in October 1997 - and finance a tender offer to repurchase its $100 mil. in 7.05% debentures due June 1, 2026. The offering, which is anticipated to close on March 4, consists of $160 mil. in senior notes due March 4, 2003, with an annual interest rate of 7.1% and $240 mil. in senior notes due March 4, 2008, with an annual interest rate of 7.45%...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.